LAM Extra for General Practicioners

[CHRONIC COUGH - THE OTOLARYNGOLOGISTS’ POINT OF VIEW]

GERLINGER Imre

OCTOBER 12, 2009

LAM Extra for General Practicioners - 2009;1(04)

[Chronic cough can have a profound impact on the psychosocial function of patients. Most studies agree that post-nasal drip syndrome (PNDS), asthma, gastro-esophageal reflux disease (GERD), and laryngo-pharyngeal reflux (LPR) are the most common causes of chronic cough in immunocompetent, non-smoking patients who are not taking angiotensin-converting enzyme (ACE) inhibitors and present with a negative chest x-ray. No diagnostic test has yet been found to define those who have PNDS other than the response to a first-generation antihistamine. Examination of the available evidence suggests that the theory of mechanical stimulation of the pharynx by mucus does not explain the occurrence of cough. Inflammatory mediators’ levels in the lower airways are higher in PNDS, cough variant asthma, and GERD, and the theory that an inflammatory process is affecting “one airway” is a plausible one. Nasal disease is more likely to result in cough from the co-existing involvement of the lower airways through a yet undefined pathway. Mediation by eosinophil and mast cells appears to be a likely mechanism. In this paper, the author summarizes all potential pulmonological, otolaryngological and other reasons of chronic cough, suggesting a systematic therapeutic algorithm.]

COMMENTS

0 comments

Further articles in this publication

LAM Extra for General Practicioners

[EFFECT OF BETA BLOCKERS IN HYPERTENSION, ISCHAEMIC HEART DISEASE, HEART FAILURE AND METABOLIC SYNDROME]

BENCZÚR Béla

[Beta-blockers are among the most widely used drugs for the treatment of cardiovascular diseases. In the mid-90’s, these drugs were recommended as first-line therapies of hypertension. With the introduction of new drugs, the list of first-choice drugs has been extended. The results of recently published major hypertension trials, which compared conventional agents (beta blockers and/or diuretics) with newer agents (angiotensin converting enzyme inhibitors, Caantagonists, angiotensin receptor blockers), raised concerns regarding the role of beta blockers in cardiovascular primary prevention. Subsequently, a metaanalysis of 13 trials has shown that compared with other drug types, beta-blocker therapy is less beneficial in patients with hypertension who do not have heart disease. Nevertheless, in cardiovascular indications other than hypertension (acute myocardial infarction, heart failure and arrhythmias), betablockers retain their dominant position.]

All articles in the issue

Related contents

Lege Artis Medicinae

[THE INFLUENCE OF GASTROESOPHAGEAL REFLUX DISEASE AND ITS TREATMENT ON ASTHMATIC COUGH]

BÖCSKEI Csaba, VICZIÁN Magdolna, BÖCSKEI Renáta, HORVÁTH Ildikó

[INTRODUCTION - Gastroesophageal reflux is known to cause chronic cough and it is also implicated in worsening of asthma. We conducted a prospective study to examine the clinical significance of gastroesophageal reflux disease in asthmatic patients with chronic cough, to analyse the temporal relationship between reflux events and coughing and to assess the effect of esomeprazole treatment on respiratory symptoms and lung function in these patients. PATIENTS AND METHODS - 126 asthmatic patients with chronic dry cough were studied. Diagnosis of gastroesophageal reflux disease was based on typical symptoms and the effectiveness of therapeutic test or on pH monitoring, while control group consisted of the patients without gastroesophageal reflux (negative pH results). The study group patients received the proton pump inhibitor esomeprazole (40 mg/day for three months) and standard treatment for asthma was continued. During the study pulmonary function tests (forced expiratory volume in one second and peak expiratory flow) were evaluated four times and the reflux symptom scores as well, using a questionnaire. RESULTS - The results of pH monitoring showed that 64% of cough episodes were related to acid reflux and in 91% of reflux events preceded coughing. Esomeprazole treatment (40 mg/day for three months) not only diminished gastroesophageal reflux symptoms but also improved asthma outcome measures. Baseline pulmonary function values increased significantly together with a decrease in symptom scores and the use of rescue medication. In most patients included in the extended part of the study for another three months, the dose of inhaled steroids could be reduced with sustained therapy against gastroesophageal reflux. CONCLUSION - Our data shows that reflux events preceded coughing in most cases and that treatment of gastroesophageal reflux disease caused an improvement in different outcome measures of asthma suggest that gastroesophageal reflux disease worsens asthma and its treatment is of clinical importance in the effective management of these patients.]

Lege Artis Medicinae

[Focus on the diagnosis and therapy of chronic cough]

SZILASI Mária

[Cough by itself is not a disease but a part of a complex defense mechanism protecting from harmful materials entering the airways and cleaning the lungs and airways from potentially harmful materials. Normally, cough is accompanied by other defense mechanisms (bronchoconstriction and secretion of sputum) that increase the effectiveness of cough. Cough generally is caused by intrapulmonary disorders, but may be related to extrapulmonary lesions that are not easy to diagnose. In every case, an etiological diagnosis has to be the aim because this is the only way to proper treatment. From the abundance of reasons for cough, upper airway cough syndrome, asthma, chronic obstructive pulmonary disease, and gastro-esophageal reflux disease are discussed in detail.]

Hypertension and nephrology

[Change in prescribing RAS inhibitors with respect of data of National Health Insurance Fund (NHIF)]

BARNA István, GYURCSÁNYI András

[The authors examined and analyzed monthly data of accounted prescription sales that were supported by the National Health Insurance Fund. They wished to determine how the use of angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARB) had changed. They separately evaluated how much this data was in accordance with the several, recently published articles about clinical trial results that compared inhibitors of the renin-angiotensin system (RAS inhibitors). It seemed worthwhile to examine the use of RAS inhibitors in Hungary and more specifically where RAS inhibitors stand among subsidized drugs based on the National Health Insurance Fund (OEP) database. The processed data was obtained from the National Health Insurance database, in the Decembers of 2007-2012 years and was based on prescription sales in pharmacies that were accounted for by the National Health Insurance Fund. During the data analysis we examined the number of prescriptions accounted for by looking at ATC codes and molecules, and examined the number of products (brands) available by ATC with Social Insurance Support in the given period. We examined the monthly turnover of ACE inhibitors and ARB products and the kedveamount of Social Insurance Support on these prescriptions in the given period. Next, we analyzed how much the average cost of prescriptions was by ATC codes and what kind of molecules have been available in Hungary with Social Insurance Support according to ATC codes.]

Clinical Neuroscience

[Angioneuritic edema in ischaemic stroke patients treated with rt-PA]

LOVÁSZ Rita, SAS Attila, KOLLÁR Tibor, PETERCSÁK Edina, FEKETE István, BILINSZKI Erika, VALIKOVICS Attila

[Data of our 254 patients who were treated with rt-PA between 1st of Jan, 2011 and 31st of Dec, 2014 were processed. We focused on angioneurotic oedema as allergic complication of thrombolysis which caused life threatening respiratory obstruction in two cases. We describe these two patients’ history. Out of 254 patients six (2.3%) suffered angioneurotic edema caused respiratory obstruction in two (0.90%) cases. This occurrence is approximately 1.3-5.1% in literature. Five, out of six patients who suffered from angioneurotic oedema, had been treated with ACE inhibitors or ARB before. The role of ACE inhibitors is known in metabolism of bradykinin cascade. Plasmin which present during thrombolysis, precipitates biochemical mechanisms of this potential life threatening complication. Therefore rt-PA alone can be the cause of angioedema, but it can be more frequent together with ACE inhibitors therapy.]

Lege Artis Medicinae

[NEW METHODS FOR NON-INVASIVE ASSESSMENT OF AIRWAY DISEASES]

HORVÁTH Ildikó

[In chronic obstructive airway diseases there are several unsolved questions regarding the early diagnosis, monitoring treatment, simple detection of exacerbations and the questions of differential diagnosis. These problems indicate the need for the development of new diagnostic methods and their application in clinical practice. This need is further emphasized by the fact that in most chronic airway diseases, including asthma and chronic obstructive pulmonary disease inflammation has a central role in the pathomechanism and its suppression is the main aim of treatment, but so far, we do not have adequate method for the assessment of inflammation intensity in clinical practice. In recent decades non-invasive sampling techniques directly from the airways have made a progress in respiratory research and at present some of them are available for clinical use. Among these techniques sputum induction, measurement of exhaled biomarkers including exhaled nitric oxide and mediators in exhaled breath condensate samples are used increasingly. The present review summarises our current knowledge on these methods and the most important findings obtained by their applications.]